HomeNewsBusinessMost mutual funds may fail to benefit from RBI’s liquidity window - here is why: Report

Most mutual funds may fail to benefit from RBI’s liquidity window - here is why: Report

To avail the Rs 50,000 crore liquidity window till May 11, funds will be allowed to borrow against investment grade credit risk schemes

April 28, 2020 / 09:27 IST
Story continues below Advertisement

Most mutual funds may fail to take advantage of the liquidity window provided by the Reserve Bank of India (RBI) as many credit risk schemes are low on top-rated papers - offloaded due to redemption pressure from the coronavirus pandemic, The Economic Times reported.

To avail the Rs 50,000 crore liquidity window till May 11, set up for the mutual fund (MF) sector by the RBI, funds will be allowed to borrow against investment grade credit risk schemes.

Story continues below Advertisement

Industry officials, however, are concerned this may not be enough as banks may be unwilling to accept the majority of the low-rated securities as collateral, especially since the period of holding is short – only till May 11, they told the paper.

Follow our LIVE Updates on the coronavirus pandemic here

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show